| Literature DB >> 26084319 |
Samaneh Farashi1, Nooshin Bayat, Negin Faramarzi Garous, Mehri Ashki, Mona Montajabi Niat, Shadi Vakili, Hashem Imanian, Sirous Zeinali, Hossein Najmabadi, Azita Azarkeivan.
Abstract
The 3.7 kb triplicated α-globin gene (ααα(anti 3.7)) mutation has been found in most populations. It results from an unequal crossover between misaligned homologous segments in the α-globin gene cluster during meiosis. The pathophysiology and clinical severity of β-thalassemia (β-thal) are associated with the degree of α chain imbalance. The excess of α-globin chains plays an important role in the pathophysiology of β-thal. When heterozygous/homozygous β-thal coexists with an α gene numerical alteration, the clinical and hematological phenotype of thalassemia could change to mild anemia in case of an α deletion (-α/αα) or severe anemia in the case of an α triplication (αα/ααα). The coexistence of an ααα(anti 3.7) triplication is considered an important factor in the severity of β-thal, exacerbating the phenotypic severity of β-thal by causing more globin chain imbalance. This study shows that the ααα(anti 3.7) triplication is an important factor in the causation of β-thal intermedia (β-TI) in heterozygous β-thal. This type of phenotype modification has rarely been observed and reported in the Iranian population. Here we report the coinheritance of a triplicated α-globin gene arrangement and heterozygous/homozygous β-thal in 23 cases, presenting with a β-TI or β-thal major (β-TM) phenotype. Some of these patients were considered to have a mild β-TI phenotype as they needed no blood transfusions; some occasionally received blood transfusions in their lifetime (for example on delivery) but some are dependent on regular blood transfusions (every 20 to 40 days). Our study was focused on the importance of detecting the α-globin gene triplication in genotype/phenotype prediction in Iranian thalassemia patients.Entities:
Keywords: blood transfusion(s); αααanti 3.7 Triplication; β-thalassemia intermedia (β-TI); β-thalassemia major (β-TM)
Mesh:
Substances:
Year: 2015 PMID: 26084319 DOI: 10.3109/03630269.2015.1027914
Source DB: PubMed Journal: Hemoglobin ISSN: 0363-0269 Impact factor: 0.849